about
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancerPhase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerCarcinosarcoma of the ovary: natural history, patterns of treatment, and outcomeIdentifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics TechnologyClinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancerComparative effectiveness research in oncology methodology: observational data.Using publicly reported hospital data to predict obstetric quality.Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.Changes in vitamin and mineral supplement use after breast cancer diagnosis in the Pathways Study: a prospective cohort study.How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancerAdjuvant treatment for elderly patients with early-stage lung cancer treated with limited resection.Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) StudyA prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies.Disparities in breast cancer care and research: report from a Breast Cancer Research Foundation sponsored workshop, 9-10 October 2014Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialAn economic analysis of robotically assisted hysterectomy.Quality of life among women recently diagnosed with invasive breast cancer: the Pathways Study.Safety and tolerance of radical hysterectomy for cervical cancer in the elderlyEarly discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patientsThe commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals.Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease.Contraindicated use of bevacizumab and toxicity in elderly patients with cancerBone health history in breast cancer patients on aromatase inhibitors.Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancerVariations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study.Use of guideline-based antibiotic prophylaxis in women undergoing gynecologic surgery.Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium.Uterine pathology in women undergoing minimally invasive hysterectomy using morcellationComparative effectiveness of robotically assisted compared with laparoscopic adnexal surgery for benign gynecologic disease.Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study.The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer.Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patientsAssociation between plasma 25-hydroxyvitamin D and breast cancer risk.Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk.
P50
Q24632347-93B35244-2116-4D56-A700-7328A4DFF234Q28240692-1C7F6DE8-4CE8-41D9-82A4-66BC2C60913FQ28294243-2B57488C-00FD-4DD8-A1B0-3697FEF4D3AAQ28551798-A766D7CE-F2CC-4433-8078-5AD31B5E8339Q30372504-3AAB0393-CFE0-4635-8055-004646AAA5A2Q30573657-2315B251-376F-4CF5-AD63-36D6B05D54CEQ31130377-84E0E840-1D90-4BA7-81C0-799DB089D92BQ33358885-F3890D74-862E-43BD-81C1-1AF8F0259855Q33736180-4CA4AC20-7E81-41C0-90ED-1B80554533EBQ33762649-53B49DFC-64CF-48D9-BA9E-E14940B13E8FQ33767120-BDF02267-EF14-46CD-B9E5-E43314A563F9Q33774527-8F1141DE-50C1-4771-ACFF-D2D9902F252EQ33811206-C153C8DE-89DD-42B2-8D36-F313E5F8A607Q33834834-E03305A0-5F59-4001-AAC5-AE71AF04540AQ33857602-A324AE3D-69FB-481F-ADD2-9CB8B656AF92Q33890476-C9F73FC8-9BFF-409E-8AE5-DE0386B93653Q33914764-0CEBFA31-AB35-4624-9F97-DE67D59B0E5EQ33915034-77BC05CD-5626-4AAD-9BB5-8B6969F705DAQ33915071-9C7E6952-DF2B-4A98-B89E-7C5692BCA912Q34089701-4A853EFE-28D5-47A9-8E5B-4619D1F01733Q34111467-51CE2E24-68D7-4449-8675-F10B9D5C9DB1Q34150745-7C692685-8318-4C1F-BC73-D6B2F645C497Q34193946-DEC16D1F-A768-4712-8718-402676B462A6Q34290454-9943E7EA-0932-49DC-8708-55DABE386582Q34328614-A48FC4EB-7A25-4C80-A83F-2AFC7A1DE87CQ34368413-906F3892-7E36-41B3-96FC-F4C4F9583316Q34421028-D179F36C-43DF-4F0A-904E-90DFCDCB3FCFQ34421696-CD367A08-6FCC-46D4-8D7D-D3BE93DB69F0Q34482381-031204F2-E6CB-4FCB-916A-E642B3EE5067Q34497167-B9D67DF0-934B-4194-BE76-2839D2F3F48EQ34504603-C6BADDAF-6B7C-4103-AD37-D0A86CBAB4CDQ34508411-66F48637-3194-4F53-8B54-FCFF58E1434FQ34609549-74FC12AB-DE2E-4D15-80D8-F89BB481E11EQ34609661-3F8650C2-EB7F-44B8-A129-269ED82DED42Q34652701-1F7C3A50-48E2-41C2-82AF-D6B57A9D777DQ34736154-21DA3113-8BCA-46D2-866A-A27A01EE2DB2Q34737424-DE026D89-6CCF-453E-A0CC-ECCF7DF4B8E8Q34765518-440607C5-7CD2-4F55-9A43-04BE8DD40EB6Q34800991-70413A33-3537-42F4-81BF-E5D040A30D90Q34995929-7A024204-534D-435D-85A6-B8E43C260CC7
P50
name
Dawn L Hershman
@en
type
label
Dawn L Hershman
@en
prefLabel
Dawn L Hershman
@en